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INTRODUCTION:
Host defense peptides represent a promising new approach to inhibit infection. The anti-infective actions of these peptides are primarily due to their immunomodulatory effects. Since they regulate multiple aspects of the mammalian immune system, host defense peptides are also less likely to induce bacterial resistance than are traditional antibiotics. The purpose of this project is to assess whether host defense peptides are a promising strategy for treating infected orthopaedic implants. The scope of the project is to measure effects of host defense peptides on macrophages in vitro and on implants infected with Staph. aureus or Acinetobacter baumannii in our murine model of implant osseointegration.
BODY:
Progress in this year has primarily been in three areas or research. The first primary area of progress is the in vitro effects of the host defense peptides. We have found that the host defense peptide IDR-1018 stimulates production of MCP-1 (Fig. 1) . IDR-1018 also inhibits the ability of LPS to stimulate production of TNFα and MCP-1 (Fig. 2) . Thus, the effects of IDR-1018 are similar to what has been reported in the literature [1] but the effect in Figure 2B has not been shown previously. The results in Figure 2B suggest that anti-infective effects of IDR-1018 are likely more complex than the previous understanding which was that the anti-infective effects are primarily due to stimulation of production of chemokines such as MCP-1. The second primary area of progress is the in vivo effects of IDR-1018 on infection with S. aureus. IDR-1018 reduced the rate of gross integration failures from 60% (6 of 10 mice) to 33% (3 of 9 mice). IDR-1018 also modestly increased osseointegration as assessed by biomechanical pull-out testing (Fig. 3A-C) . IDR-1018 also reduced bacterial burden as assessed by bioluminescence (Fig. 3D ) and by measuring colony forming units (CFUs) and Lux gene copies in the surrounding bone ( Fig. 3E-F) . In contrast, bacteria adherent to the implants were not affected ( Fig. 3E-F) . Those results are likely due to the adherent bacteria forming a biofilm which protects them from the host immune system. Those results also suggest that IDR-1018 may be substantially more effective when applied in combination with removal of the infected implant hardware, which is the most likely clinical scenario. The host defense peptides have the potential to substantially reduce infections of fractures sustained on the battlefield and in civilian settings. If the synthetic peptide reduces infections in the studies proposed in this application, more extensive pre-clinical testing would precisely determine its potential benefits and risks and determine whether the peptide is a high priority for human trials.
Introduction Fig 1. IDR-1018 Reduces Bacterial Burden
Orthopaedic implant infection is becoming increasingly difficult to treat due to the prevalence of multiple-drug-resistant bacteria. Host defense peptides are less likely than antibiotics to induce bacterial resistance because they decrease infection primarily by recruiting and activating macrophages rather than by directly killing the bacteria [1] . IDR-1018 is a novel small synthetic host defense peptide that decreases soft tissue infections [2 and 3] .
The purpose of the current study was to determine whether IDR-1018 decreases implant infection and would therefore prevent impaired osseointegration due to infection.
Materials and Methods
Results Discussion
Bacteriostatic and bactericidal effects on Staphylococcus aureus
The minimal inhibitory and minimal bactericidal concentration (MIC and MBC) of IDR-1018 on S. aureus were determined in both Mueller Hinton Broth and physiological saline.
Effects on implant infection:
• Bioluminescent S. aureus (Xen36 strain, Caliper Life Sciences) were adhered to titanium alloy implants (1 mm diameter, 3.2 mm length) before insertion into pilot holes in the mid-diaphysis of the femur of 6-8 week old mice [4 and 5].
• IDR-1018 (200ug/injection) or saline was administrated i.p. daily beginning 4 hours before implant insertion and 24 and 48 hours after implant insertion.
• Mice were euthanized at 15 days post operation.
• Bacterial burden was quantified by non-invasive bioluminescence imaging (BLI:
Xenogen IVIS 200 system) as well as by counting colony forming units (CFUs) and Lux gene on the implants and in the bones.
• Osseointegration was measured by biomechanical pull-out testing as previously described for this murine implant model [4 and 5].
IDR-1018
• reduced implant infection and therefore prevented impaired osseointegration (Fig 1 and 2 ).
• has less effect on the bacteria adherent to the implant because biofilm-formation on the implant likely protect the bacteria from the antibacterial effect of IDR1018.
• potentially acts by recruiting and/or activating inflammatory cells [3] rather than by directly killing the bacteria in physiological ionic strength (Fig1.A) and therefore is unlikely to induce bacterial resistance.
Future study
IDR-1018 may be more effective in combination with antibiotics and/or implant removal. Evaluation of these possibilities is especially important because IDR-1018 is likely to be clinically used in combination with both antibiotics and implant removal. 
